Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21716844 | 0.96 | L3MBTL1 (0.36) | L3MBTL1KDM4EATMCYP1A2PDE10A | |
| SCHEMBL21716245 | 0.91 | CYP1A2 (0.32) | L3MBTL1KDM4EATMCYP1A2PDE10A | |
| SCHEMBL21716256 | 0.89 | KDM4E (0.35) | L3MBTL1KDM4EATMCYP1A2 | |
| SCHEMBL21717664 | 0.88 | KDM4E (0.32) | L3MBTL1KDM4EATMCYP1A2PDE10A | |
| SCHEMBL21717599 | 0.85 | — | — | |
| SCHEMBL21716887 | 0.84 | KDM4E (0.38) | L3MBTL1KDM4EATMCYP1A2 | |
| SCHEMBL21716868 | 0.84 | GSR (0.33) | L3MBTL1KDM4EATMCYP1A2 | |
| SCHEMBL21717626 | 0.84 | GSR (0.33) | L3MBTL1KDM4EATMCYP1A2 | |
| SCHEMBL21716380 | 0.83 | AURKA (0.33) | L3MBTL1KDM4EATM | |
| SCHEMBL21716972 | 0.83 | CYP1A2 (0.31) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11192884-B2 | Heterocyclic compound and organic light-emitting device comprising same | LG CHEM, LTD. (KR) | 2021-12-07 | — | — | US | disclosed |
| US-20200048226-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192884-B2 | Heterocyclic compound and organic light-emitting device comprising same | CYP1A1, CYP1B1, CRY1 | L3MBTL1 1427/4885KDM4E 1813/4885ATM 3428/4885 |
| US-20200048226-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | CYP1A1, CYP1B1, CRY1 | L3MBTL1 1427/4885KDM4E 1813/4885ATM 3428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.